The Latin America, Middle East and Africa Cervical Cancer Diagnostic Market would witness market growth of 7.6% CAGR during the forecast period (2023-2029).
Cervical cancer is the fourth most frequent cancer and the main cause of mortality for women. Large pharmaceutical corporations are actively researching the best remedies for the same. Many potential pharmaceuticals and biologics are currently undergoing clinical testing. During the forecast period, the market is expected to develop due to the introduction of technologically improved computer-guided cervical cancer screening tests designed to decrease false-negative test results and increase accuracy.
Infection with the human papillomavirus (HPV) is the primary risk factor for developing cervical cancer. The majority of infections occur as a result of sexual activity, and the majority of people recover completely without any complications after contracting the virus. More than one hundred different types of HPV have been identified. The types or strains of HPV that are most commonly associated with an increased risk of cervical cancer include HPV16 and HPV18.
A weaker immune system increases the likelihood of acquiring cervical cancer in a person. Immune suppression by corticosteroid drugs, organ donation, therapies for different types of cancer, or the human immunodeficiency virus (HIV), the virus that causes acquired immune deficiency syndrome (AIDS), can all lead to a weakened immune system. A person's immune system is less competent to combat early cancer when they have HIV Herpes. Cervical cancer is more likely to strike those with genital herpes.
According to data from the “National Hospital Registry of Cancer” (NHRC), 20% of patients with cervical and vaginal cancer and 51% of those with endometrial cancer had their condition classified as International Federation of Gynecology and Obstetrics (FIGO) stage I. Because of this, the government is making more efforts to raise awareness of these diseases and the available preventative measures. The region's rising cervical cancer incidence will spur demand for diagnostics for early diagnosis and treatment, which will fuel market expansion in LAMEA.
The Brazil market dominated the LAMEA Cervical Cancer Diagnostic Market by Country in 2022 and would continue to be a dominant market till 2029; thereby, achieving a market value of $172.3 Million by 2029. The Argentina market is experiencing a CAGR of 8.1% during (2023 - 2029). Additionally, The UAE market would showcase a CAGR of 7.3% during (2023 - 2029).
Based on Type, the market is segmented into Pap Smear Tests, Colposcopy Tests, HPV Test, Biopsy & ECC, and Others. Based on Age Group, the market is segmented into 20 to 40 years, and Above 40 years. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
Free Valuable Insights: The Worldwide Cervical Cancer Diagnostic Market is Projected to reach USD 10.2 Billion by 2029, at a CAGR of 4.4%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Abbott Laboratories, Becton, Dickinson and Company, Carl Zeiss AG, CooperSurgical, Inc. (The Cooper Companies, Inc.), DYSIS Medical, Inc., F. Hoffmann-La Roche Ltd., Hologic, Inc., Qiagen N.V., Siemens Healthineers AG (Siemens AG) and Thermo Fisher Scientific, Inc.
Scope of the Study
Market Segments Covered in the Report:
By Type
- Pap Smear Tests
- Colposcopy Tests
- HPV Test
- Biopsy & ECC
- Others
By Age Group
- 20 to 40 years
- Above 40 years
By Country
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
Key Market Players
List of Companies Profiled in the Report:
- Abbott Laboratories
- Becton, Dickinson and Company
- Carl Zeiss AG
- CooperSurgical, Inc. (The Cooper Companies, Inc.)
- DYSIS Medical, Inc.
- F.Hoffmann-La Roche Ltd.
- Hologic, Inc.
- Qiagen N.V.
- Siemens Healthineers AG (Siemens AG)
- Thermo Fisher Scientific, Inc.
Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 LAMEA Cervical Cancer Diagnostic Market, by Type
1.4.2 LAMEA Cervical Cancer Diagnostic Market, by Age Group
1.4.3 LAMEA Cervical Cancer Diagnostic Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market composition & scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Competition Analysis - Global
3.1 KBV Cardinal Matrix
3.1.1 Partnerships, Collaborations and Agreements
3.1.2 Product Launches and Product Expansions
3.1.3 Acquisition and Mergers
3.1.4 Approvals and Trials
3.1.5 Geographical and Business Expansions
3.2 Top Winning Strategies
3.2.1 Key Leading Strategies: Percentage Distribution (2019-2023)
Chapter 4. LAMEA Cervical Cancer Diagnostic Market by Type
4.1 LAMEA Pap Smear Tests Market by Country
4.2 LAMEA Colposcopy Tests Market by Country
4.3 LAMEA HPV Test Market by Country
4.4 LAMEA Biopsy & ECC Market by Country
4.5 LAMEA Others Market by Country
Chapter 5. LAMEA Cervical Cancer Diagnostic Market by Age Group
5.1 LAMEA 20 to 40 years Market by Country
5.2 LAMEA Above 40 years Market by Country
Chapter 6. LAMEA Cervical Cancer Diagnostic Market by Country
6.1 Brazil Cervical Cancer Diagnostic Market
6.1.1 Brazil Cervical Cancer Diagnostic Market by Type
6.1.2 Brazil Cervical Cancer Diagnostic Market by Age Group
6.2 Argentina Cervical Cancer Diagnostic Market
6.2.1 Argentina Cervical Cancer Diagnostic Market by Type
6.2.2 Argentina Cervical Cancer Diagnostic Market by Age Group
6.3 UAE Cervical Cancer Diagnostic Market
6.3.1 UAE Cervical Cancer Diagnostic Market by Type
6.3.2 UAE Cervical Cancer Diagnostic Market by Age Group
6.4 Saudi Arabia Cervical Cancer Diagnostic Market
6.4.1 Saudi Arabia Cervical Cancer Diagnostic Market by Type
6.4.2 Saudi Arabia Cervical Cancer Diagnostic Market by Age Group
6.5 South Africa Cervical Cancer Diagnostic Market
6.5.1 South Africa Cervical Cancer Diagnostic Market by Type
6.5.2 South Africa Cervical Cancer Diagnostic Market by Age Group
6.6 Nigeria Cervical Cancer Diagnostic Market
6.6.1 Nigeria Cervical Cancer Diagnostic Market by Type
6.6.2 Nigeria Cervical Cancer Diagnostic Market by Age Group
6.7 Rest of LAMEA Cervical Cancer Diagnostic Market
6.7.1 Rest of LAMEA Cervical Cancer Diagnostic Market by Type
6.7.2 Rest of LAMEA Cervical Cancer Diagnostic Market by Age Group
Chapter 7. Company Profiles
7.1 Abbott Laboratories
7.1.1 Company Overview
7.1.2 Financial Analysis
7.1.3 Segmental and Regional Analysis
7.1.4 Research & Development Expense
7.1.5 SWOT Analysis
7.2 Becton, Dickinson and Company
7.2.1 Company Overview
7.2.2 Financial Analysis
7.2.3 Segmental and Regional Analysis
7.2.4 Research & Development Expense
7.2.5 Recent strategies and developments:
7.2.5.1 Partnerships, Collaborations, and Agreements:
7.2.5.2 Product Launches and Product Expansions:
7.2.5.3 Acquisition and Mergers:
7.2.6 SWOT Analysis
7.3 Carl Zeiss AG
7.3.1 Company Overview
7.3.2 Financial Analysis
7.3.3 Segmental and Regional Analysis
7.3.4 Research & Development Expenses
7.4 CooperSurgical, Inc. (The Cooper Companies, Inc.)
7.4.1 Company Overview
7.4.2 Financial Analysis
7.4.3 Segmental and Regional Analysis
7.4.4 Research & Development Expense
7.5 DYSIS Medical, Inc.
7.5.1 Company Overview
7.5.2 Recent strategies and developments:
7.5.2.1 Product Launches and Product Expansions:
7.6 F. Hoffmann-La Roche Ltd.
7.6.1 Company Overview
7.6.2 Financial Analysis
7.6.3 Segmental and Regional Analysis
7.6.4 Research & Development Expense
7.6.5 Recent strategies and developments:
7.6.5.1 Partnerships, Collaborations, and Agreements:
7.6.5.2 Product Launches and Product Expansions:
7.6.5.3 Acquisition and Mergers:
7.7 Hologic, Inc.
7.7.1 Company Overview
7.7.2 Financial Analysis
7.7.3 Segmental and Regional Analysis
7.7.4 Research & Development Expenses
7.7.5 Recent strategies and developments:
7.7.5.1 Partnerships, Collaborations, and Agreements:
7.7.5.2 Product Launches and Product Expansions:
7.7.5.3 Geographical Expansions:
7.8 Qiagen N.V.
7.8.1 Company Overview
7.8.2 Financial Analysis
7.8.3 Regional Analysis
7.8.4 Research & Development Expense
7.8.5 Recent strategies and developments:
7.8.5.1 Partnerships, Collaborations, and Agreements:
7.8.5.2 Product Launches and Product Expansions:
7.8.5.3 Acquisition and Mergers:
7.9 Siemens Healthineers AG (Siemens AG)
7.9.1 Company Overview
7.9.2 Financial Analysis
7.9.3 Segmental and Regional Analysis
7.9.4 Research & Development Expense
7.9.5 SWOT Analysis
7.10. Thermo Fisher Scientific, Inc.
7.10.1 Company Overview
7.10.2 Financial Analysis
7.10.3 Segmental and Regional Analysis
7.10.4 Research & Development Expenses
7.10.5 SWOT Analysis
TABLE 1 LAMEA Cervical Cancer Diagnostic Market, 2019 - 2022, USD Million
TABLE 2 LAMEA Cervical Cancer Diagnostic Market, 2023 - 2029, USD Million
TABLE 3 Partnerships, Collaborations and Agreements– Cervical Cancer Diagnostic Market
TABLE 4 Product Launches And Product Expansions– Cervical Cancer Diagnostic Market
TABLE 5 Acquisition and Mergers– Cervical Cancer Diagnostic Market
TABLE 6 Approvals and trials– Cervical Cancer Diagnostic Market
TABLE 7 Geographical and Business Expansions– Cervical Cancer Diagnostic Market
TABLE 8 LAMEA Cervical Cancer Diagnostic Market by Type, 2019 - 2022, USD Million
TABLE 9 LAMEA Cervical Cancer Diagnostic Market by Type, 2023 - 2029, USD Million
TABLE 10 LAMEA Pap Smear Tests Market by Country, 2019 - 2022, USD Million
TABLE 11 LAMEA Pap Smear Tests Market by Country, 2023 - 2029, USD Million
TABLE 12 LAMEA Colposcopy Tests Market by Country, 2019 - 2022, USD Million
TABLE 13 LAMEA Colposcopy Tests Market by Country, 2023 - 2029, USD Million
TABLE 14 LAMEA HPV Test Market by Country, 2019 - 2022, USD Million
TABLE 15 LAMEA HPV Test Market by Country, 2023 - 2029, USD Million
TABLE 16 LAMEA Biopsy & ECC Market by Country, 2019 - 2022, USD Million
TABLE 17 LAMEA Biopsy & ECC Market by Country, 2023 - 2029, USD Million
TABLE 18 LAMEA Others Market by Country, 2019 - 2022, USD Million
TABLE 19 LAMEA Others Market by Country, 2023 - 2029, USD Million
TABLE 20 LAMEA Cervical Cancer Diagnostic Market by Age Group, 2019 - 2022, USD Million
TABLE 21 LAMEA Cervical Cancer Diagnostic Market by Age Group, 2023 - 2029, USD Million
TABLE 22 LAMEA 20 to 40 years Market by Country, 2019 - 2022, USD Million
TABLE 23 LAMEA 20 to 40 years Market by Country, 2023 - 2029, USD Million
TABLE 24 LAMEA Above 40 years Market by Country, 2019 - 2022, USD Million
TABLE 25 LAMEA Above 40 years Market by Country, 2023 - 2029, USD Million
TABLE 26 LAMEA Cervical Cancer Diagnostic Market by Country, 2019 - 2022, USD Million
TABLE 27 LAMEA Cervical Cancer Diagnostic Market by Country, 2023 - 2029, USD Million
TABLE 28 Brazil Cervical Cancer Diagnostic Market, 2019 - 2022, USD Million
TABLE 29 Brazil Cervical Cancer Diagnostic Market, 2023 - 2029, USD Million
TABLE 30 Brazil Cervical Cancer Diagnostic Market by Type, 2019 - 2022, USD Million
TABLE 31 Brazil Cervical Cancer Diagnostic Market by Type, 2023 - 2029, USD Million
TABLE 32 Brazil Cervical Cancer Diagnostic Market by Age Group, 2019 - 2022, USD Million
TABLE 33 Brazil Cervical Cancer Diagnostic Market by Age Group, 2023 - 2029, USD Million
TABLE 34 Argentina Cervical Cancer Diagnostic Market, 2019 - 2022, USD Million
TABLE 35 Argentina Cervical Cancer Diagnostic Market, 2023 - 2029, USD Million
TABLE 36 Argentina Cervical Cancer Diagnostic Market by Type, 2019 - 2022, USD Million
TABLE 37 Argentina Cervical Cancer Diagnostic Market by Type, 2023 - 2029, USD Million
TABLE 38 Argentina Cervical Cancer Diagnostic Market by Age Group, 2019 - 2022, USD Million
TABLE 39 Argentina Cervical Cancer Diagnostic Market by Age Group, 2023 - 2029, USD Million
TABLE 40 UAE Cervical Cancer Diagnostic Market, 2019 - 2022, USD Million
TABLE 41 UAE Cervical Cancer Diagnostic Market, 2023 - 2029, USD Million
TABLE 42 UAE Cervical Cancer Diagnostic Market by Type, 2019 - 2022, USD Million
TABLE 43 UAE Cervical Cancer Diagnostic Market by Type, 2023 - 2029, USD Million
TABLE 44 UAE Cervical Cancer Diagnostic Market by Age Group, 2019 - 2022, USD Million
TABLE 45 UAE Cervical Cancer Diagnostic Market by Age Group, 2023 - 2029, USD Million
TABLE 46 Saudi Arabia Cervical Cancer Diagnostic Market, 2019 - 2022, USD Million
TABLE 47 Saudi Arabia Cervical Cancer Diagnostic Market, 2023 - 2029, USD Million
TABLE 48 Saudi Arabia Cervical Cancer Diagnostic Market by Type, 2019 - 2022, USD Million
TABLE 49 Saudi Arabia Cervical Cancer Diagnostic Market by Type, 2023 - 2029, USD Million
TABLE 50 Saudi Arabia Cervical Cancer Diagnostic Market by Age Group, 2019 - 2022, USD Million
TABLE 51 Saudi Arabia Cervical Cancer Diagnostic Market by Age Group, 2023 - 2029, USD Million
TABLE 52 South Africa Cervical Cancer Diagnostic Market, 2019 - 2022, USD Million
TABLE 53 South Africa Cervical Cancer Diagnostic Market, 2023 - 2029, USD Million
TABLE 54 South Africa Cervical Cancer Diagnostic Market by Type, 2019 - 2022, USD Million
TABLE 55 South Africa Cervical Cancer Diagnostic Market by Type, 2023 - 2029, USD Million
TABLE 56 South Africa Cervical Cancer Diagnostic Market by Age Group, 2019 - 2022, USD Million
TABLE 57 South Africa Cervical Cancer Diagnostic Market by Age Group, 2023 - 2029, USD Million
TABLE 58 Nigeria Cervical Cancer Diagnostic Market, 2019 - 2022, USD Million
TABLE 59 Nigeria Cervical Cancer Diagnostic Market, 2023 - 2029, USD Million
TABLE 60 Nigeria Cervical Cancer Diagnostic Market by Type, 2019 - 2022, USD Million
TABLE 61 Nigeria Cervical Cancer Diagnostic Market by Type, 2023 - 2029, USD Million
TABLE 62 Nigeria Cervical Cancer Diagnostic Market by Age Group, 2019 - 2022, USD Million
TABLE 63 Nigeria Cervical Cancer Diagnostic Market by Age Group, 2023 - 2029, USD Million
TABLE 64 Rest of LAMEA Cervical Cancer Diagnostic Market, 2019 - 2022, USD Million
TABLE 65 Rest of LAMEA Cervical Cancer Diagnostic Market, 2023 - 2029, USD Million
TABLE 66 Rest of LAMEA Cervical Cancer Diagnostic Market by Type, 2019 - 2022, USD Million
TABLE 67 Rest of LAMEA Cervical Cancer Diagnostic Market by Type, 2023 - 2029, USD Million
TABLE 68 Rest of LAMEA Cervical Cancer Diagnostic Market by Age Group, 2019 - 2022, USD Million
TABLE 69 Rest of LAMEA Cervical Cancer Diagnostic Market by Age Group, 2023 - 2029, USD Million
TABLE 70 Key Information – Abbott Laboratories
TABLE 71 Key information – Becton, Dickinson and Company
TABLE 72 key Information – Carl Zeiss AG
TABLE 73 Key Information – CooperSurgical, Inc.
TABLE 74 Key information – DYSIS Medical, Inc.
TABLE 75 KEY INFORMATION – F. Hoffmann-La Roche Ltd.
TABLE 76 Key Information – Hologic, Inc.
TABLE 77 Key Information – Qiagen N.V.
TABLE 78 Key Information – Siemens Healthineers AG
TABLE 79 Key Information – Thermo Fisher Scientific, Inc.
List of Figures
FIG 1 Methodology for the research
FIG 2 KBV Cardinal Matrix
FIG 3 Key Leading Strategies: Percentage Distribution (2019-2023)
FIG 4 LAMEA Cervical Cancer Diagnostic Market share by Type, 2022
FIG 5 LAMEA Cervical Cancer Diagnostic Market share by Type, 2029
FIG 6 LAMEA Cervical Cancer Diagnostic Market by Type, 2019 - 2029, USD Million
FIG 7 LAMEA Cervical Cancer Diagnostic Market share by Age Group, 2022
FIG 8 LAMEA Cervical Cancer Diagnostic Market share by Age Group, 2029
FIG 9 LAMEA Cervical Cancer Diagnostic Market by Age Group, 2019 - 2029, USD Million
FIG 10 LAMEA Cervical Cancer Diagnostic Market share by Country, 2022
FIG 11 LAMEA Cervical Cancer Diagnostic Market share by Country, 2029
FIG 12 LAMEA Cervical Cancer Diagnostic Market by Country, 2019 - 2029, USD Million
FIG 13 Swot analysis: Abbott laboratories
FIG 14 Recent strategies and developments: Becton, Dickinson and Company
FIG 15 Swot analysis: Becton, Dickinson and company
FIG 16 Recent strategies and developments: F. Hoffmann-La Roche Ltd.
FIG 17 Recent strategies and developments: Hologic, Inc.
FIG 18 Recent strategies and developments: Qiagen N.V.
FIG 19 Swot analysis: Siemens AG
FIG 20 Swot analysis: thermo fisher scientific, inc.